On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Open accessThe DOI matches its Crossref record.
Abstract
The carrying out in the Bio-Chemical Laboratory of the experiments otn the secretion of organic acids in diabetes described in the previous paper supplied an opportuniity for testing the hypothesis that the internal secretion of the pancreas might be stimulated and initiated (similarly to the externial secretion) by a substance of the nature of a hormone or secretin yielded by the duodenal mucous membrane ; and that in certain cases of diabetes the appearance of sugar in the urine might be due to funictional disturbance occasioned by the absence of such an intestinial excitanit of the initernal secretion.The fact that an internal secretion of the pancreas is niecessary for the regulation of carbohydrate metabolism, and that in the absence of this secretion oxidation of dextrose canniot be carried out, with the result that death occurs from acute diabetes, has been clearly proven by the experimenits of Minkowski and v. Mering,; and others on complete and partial panicreas removal, and the history of the subject is too well-known to require detailed description here.It was suggested by Schafer that the formation of the internal pancreatic secretion might possibly bc due to peculiar nests of cells of different form and staining properties to the other secreting cells of the gland.These cells from their isolated appearanice, and after the name of the observer who first described them, are called the 'islets of Langerhans.'
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut-hormone derived GIP, secreted from enteroendocrine K-cells in the upper intestine in the duodenum and jejunum mucosae32, was initially discovered to play an integral role in the body’s response to glucose intake33,34 (Textbox).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [32]
Citations
Cited by
Items 101–200 of 278
Lisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
Calhoun, P. C., BROWN, K. S., Krusch, D. A., BARIDO, E., Farris, A., Schenk, W. G., RUDOLF, L. E., Andersen, D. K., & Hanks, J. B. (1986) · Annals of Surgery · doi:10.1097/00000658-198611000-00013 · Cited by 20
The GLP‐1 system as a therapeutic target
Edwards, M. C. B. (2005) · Annals of Medicine · doi:10.1080/07853890510037400 · Cited by 19
Fernández‐Millán, E., & Guillén, C. (2022) · Biomolecules · doi:10.3390/biom12010104 · Cited by 30
“These glucose-lowering intestinal factors were called “incretins” [42] and account for approximately 50–70% of the total insulin secreted after oral glucose administration, a phenomenon known as the “incretin effect” [43].”
BackgroundSekar, R., & Chow, B. (2012) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2012.11.017 · Cited by 24
“The study was initiated by Moore [70] based on the prior knowledge that pancreas malfunction was related to diabetes and on the proposal that Sct could stimulate pancreatic secretion.”
BackgroundNew therapies for type 2 diabetes based on glucagon-like peptide 1.
Salehi, M., & D’Alessio, D. A. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.4.382 · Cited by 22
Serum insulin levels in patients with chronic pancreatitis
Rogers, J. B., Howard, J. M., & Pairent, F. W. (1970) · The American Journal of Surgery · doi:10.1016/0002-9610(70)90029-2 · Cited by 19
Gastric Operations and Glucose Homeostasis
Breuer, R. I., Zuckerman, L., Hauch, T. W., Green, W., O’Gara, P. T., Lawrence, A. M., Foà, P. P., & Matsuyama, T. (1975) · Gastroenterology · doi:10.1016/s0016-5085(19)32450-3 · Cited by 19
Snook, L. A., Nelson, E. M., Dyck, D. J., Wright, D. C., & Holloway, G. P. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00003.2015 · Cited by 17
“Although the insulin-stimulating effects of intestinal secretions were postulated in the early 1900s (5, 30), it was not until many decades later that GIP (8) and GLP (22, 29) were characterized.”
BackgroundIncretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Knapper, J. M. E., Morgan, L., & Fletcher, J. M. (1996) · Proceedings of The Nutrition Society · doi:10.1079/pns19960030 · Cited by 17
Reed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“177 The results of this oral intake were not only negative but also inconclusive, which would be expected due to the lack of the modern-day understanding that proteins are proteolytically degraded in the stomach.”
Yada, T., Dezaki, K., & Iwasaki, Y. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00168.2025 · Cited by 16
Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes
Salvatore, T., Carbonara, O., Cozzolino, D., Torella, R., & Sasso, F. C. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802076 · Cited by 17
Glucose-Dependent Insulinotropic Polypeptide (GIP)
Wolfe, M. M., Boylan, M. O., Kieffer, T. J., & Tseng, C. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-695-9_18 · Cited by 17
Intestinale Hormone und Insulinsekretion
Pfeiffer, E. F. (1969) · Verhandlungen der Deutschen Gesellschaft für Innere Medizin · doi:10.1007/978-3-642-47085-1_62 · Cited by 16
Zheng, W., Li, L., & Li, H. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114817 · Cited by 16
Kim, H. Y., Hwang, J., Moon, M. J., & Seong, J. Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.3.320 · Cited by 17
Ore, K. A. D., Greig, N. H., Holloway, H. W., Wang, Y., Perfetti, R., & Egan, J. M. (1997) · The Journals of Gerontology Series A · doi:10.1093/gerona/52a.5.b245 · Cited by 19
Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15
Hormones of the Gastrointestinal Tract
Greengard, H. (1948) · Elsevier eBooks · doi:10.1016/b978-0-12-395712-2.50011-7 · Cited by 15
Incretin hormones and beta cell function in chronic pancreatitis.
Knop, F. K. (2010) · PubMed · Cited by 17
Kim, M., & Lee, M. (2010) · Korean Diabetes Journal · doi:10.4093/kdj.2010.34.1.2 · Cited by 18
Pancreatic Exocrine Insufficiency
Ambromovage, A. M., Pairent, F. W., & Howard, J. M. (1973) · Annals of Surgery · doi:10.1097/00000658-197303000-00016 · Cited by 14
Integration of Glucagon-Like Peptide 1 Receptor Actions Through the Central Amygdala
Duran, M., Willis, J. R., Dalvi, N., Fokakis, Z. N., VIRKUS, S., & Hardaway, J. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf019 · Cited by 13
Conlon, J. M., Patterson, S., & Flatt, P. R. (2006) · Journal of Experimental Zoology Part A Comparative Experimental Biology · doi:10.1002/jez.a.312 · Cited by 15
Using the Lymph Fistula Rat Model to Study Incretin Secretion
Yoder, S. M., Kindel, T. L., & Tso, P. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00008-4 · Cited by 16
“Although initially introduced in the early 1900s (Bayliss and Starling, 1902; Moore et al., 1906), the concept of intestinal factors stimulating the secretion of pancreatic substances did not become prevalent until the 1960s.”
BackgroundGlucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes
Ebinger, M., Jehle, D. R., Fussgaenger, R. D., Fehmann, H. C., & Jehle, P. M. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.1.e88 · Cited by 13
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 21
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Solun, B., Marcoviciu, D., & Dicker, D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0382-2 · Cited by 13
The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
Åhrén, B., Yamada, Y., & Seino, Y. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz036 · Cited by 12
“In the early 1900s, the term incretin was introduced by Starling for the stimulation of the pancreatic islets by gut hormones (1).”
Background(2011) · Wiley eBooks · doi:10.1002/9781119950424.ch5 · Cited by 12
Gastric Inhibitory Polypeptide (GIP) and Insulin Release in Duodenal Ulcer Patients*
ALAND, S. C., O’Dorisio, T. M., Crockett, S. E., & Mekhjian, H. S. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-47-3-615 · Cited by 11
GLP-1R in diabetes mellitus: from basic discovery to therapeutics development
Li, S., Huang, N., Wang, M., Huang, W., Luo, Y., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610512 · Cited by 21
“…might have a glycemic-lowering effect in diabetics, which was the fi rst study to suggest an effect of intestinal secretions on blood glucose (Moore, 1906), and in the 1960s a team of researchers in the UK and the US independently discovered the “ incretin effect, ” in which oral glucose…”
Novel role for the incretins in blood pressure regulation
Yerram, P., & Whaley‐Connell, A. T. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328356bccd · Cited by 12
“[2] demonstrated that acid gut extracts”
Update on the Acute Effects of Glucose, Insulin, and Incretins on Bone Turnover In Vivo
Sherk, V. D., Schauer, I. E., & Shah, V. N. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00598-z · Cited by 10
Secretin: Should we revisit its metabolic outcomes?
St-Pierre, D. H., & Broglio, F. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03345791 · Cited by 10
Control of Glucose Homeostasis by Incretin Hormones
Perfetti, R., Brown, T. A., Velikina, R., & Busselen, S. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317215 · Cited by 12
Signals Arising from the Gastrointestinal Tract that Affect Food Intake
Purhonen, A. (2008) · Cited by 10
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
Zhang, Z., Pan, H., Guo, L., Cai, C., Chen, T., Zhang, Z., Xu, Y., Zheng, H., Jiang, C., Wang, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01177 · Cited by 10
Discovery of dipeptidyl-peptidase IV—a 40 year journey from bench to patient
Koivisto, V. A. (2008) · Diabetologia · doi:10.1007/s00125-008-0985-0 · Cited by 9
“studied the extracts of duodenal mucosa on glycosuria in newly diagnosed diabetic patients in 1906 [6], but their data were inconsistent, perhaps because the extract was given orally.”
BackgroundAn Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Grunberger, G. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12046 · Cited by 8
Wang, L., Wu, J., Cao, H., Chen, R., Zhang, N., Fu, J., Gao, B., Zhang, J., Hou, R., Tang, C.-W., et al. (2009) · Endocrine Pathology · doi:10.1007/s12022-009-9086-y · Cited by 8
Incretins and Their Endocrine and Metabolic Functions
Seufert, J. (2017) · Endocrine development · doi:10.1159/000475730 · Cited by 9
Structure and Function of the Glucagon-Like Peptide-1 Receptor
Thorens, B., & Widmann, C. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_16 · Cited by 9
The Entero-insular Axis and the Metabolic Effects of Gastro-enteropancreatic Polypeptides
DUPRÉ, J. (1980) · Clinics in Gastroenterology · doi:10.1016/s0300-5089(21)00480-6 · Cited by 9
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“The revolutionary development of glucagon-like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity began with the initial observation of an insulinotropic effect by GLP-1 administration in both rodents and humans [18].”
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Mgbechidinma, C. L., & Ahmed, W. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100699 · Cited by 11
Tao, Y., & Liang, X. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00001-6 · Cited by 8
New Incretin Hormonal Therapies in Humans Relevant to Diabetic Cats
Reusch, C. E., & Padrutt, I. (2013) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2012.11.003 · Cited by 9
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 8
Shaefer, C. F. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.2.81 · Cited by 7
“Gut extracts were first used as a chemical excitant to treat diabetes in 1906 (2).”
MethodGlucagon-Like Peptide-1 and Its Implications in Obesity
Hurtado-Carneiro, V., Roncero, I., Blázquez, E., Álvarez, E., & Sanz, C. (2013) · InTech eBooks · doi:10.5772/54221 · Cited by 9
“Surprisingly, this effect was avoided by the administration of exendin [9-39], an antagonist of GLP-1.”
BackgroundInfluentialThe journey to understanding incretin systems: Theory, practice and more theory
Yabe, D., Kuwata, H., & Seino, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13123 · Cited by 7
“Inspired by Bayliss and Starling’s discovery of secretin in 1902, Moore et al.4 hypothesized in 1906 that gut extracts contain a hormone that regulates the endocrine pancreas, and showed that administration of these gut extracts reduces the amount of urine sugars in patients with diabetes, presumably through stimulati…”
BackgroundMethodInfluentialClinical aspects of GIP secretion
Beck, B., Villaume, C., & Debry, G. (1982) · Acta Diabetologica · doi:10.1007/bf02581180 · Cited by 8
Physiology and pathophysiology of GIP: A review
Krarup, T., & Groop, P. (1991) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365519109104567 · Cited by 8
Assessment of the incretin effect in healthy subjects: concordance between clamp and OGTT methods
Aulinger, B. A., & D’Alessio, D. A. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00104.2022 · Cited by 6
Creutzfeldt, W., & Ebert, R. (1988) · Advances in metabolic disorders · doi:10.1016/b978-0-12-027311-9.50014-7 · Cited by 7
Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman, C. (2012) · PubMed · Cited by 5
Current developments in the treatment of diabetes: the incretin therapies
Russell-Jones, D. L. (2010) · The British Journal of Diabetes · doi:10.1177/1474651409357266 · Cited by 6
Physiology and Pathophysiology of GLP-1
Göke, B., Göke, R., Fehmann, H. C., & Bode, H. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-61150-6_17 · Cited by 6
Rushakoff, R. J., Liddle, R. A., Williams, J. A., & Goldfine, I. D. (1990) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-74098-5_7 · Cited by 5
Barre, J. L., & Ledrut, J. (1934) · Archives Internationales de Physiologie · doi:10.3109/13813453409142432 · Cited by 5
Gastroentero-Pancreatic Hormones in Pregnancy
HORNNES, P. J. (1984) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.1984.12005751 · Cited by 5
Mulherin, A. J., Oh, A., Kim, H., Grieco, A., Lauffer, L., & Brubaker, P. (2011) · Obesity and metabolism · doi:10.14341/2071-8713-5305 · Cited by 4
Incretins and Regulation of Insulin Secretion
Nauck, M. A., & Meier, J. J. (2008) · Springer eBooks · doi:10.1007/978-4-431-75452-7_17 · Cited by 4
Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
Liu, Y., Kubota, S., Iizuka, K., & Yabe, D. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13302 · Cited by 5
Deshpande, M. C., Venkateswarlu, V., Mantri, A. H., & Gadewar, S. T. (2010) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2010.526123 · Cited by 3
“Reports on glucose-lowering properties of duodenal extracts, containing intestinal factors in patients suffering from diabetes mellitus, date back to 1906 (Moore, 1906).”
BackgroundTHE EFFECT OF CRUDE SECRETIN IN MATURITY-ONSET DIABETES MELLITUS
Persson, I., Juhl, F., & Svendsen, D. (1967) · The Lancet · doi:10.1016/s0140-6736(67)90857-4 · Cited by 4
Glucagon and Glucagon‐like Peptide Production and Degradation
Kieffer, T. J., Hussain, M. A., & Habener, J. F. (2001) · Comprehensive physiology · doi:10.1002/cphy.cp070208 · Cited by 5
Cholecystokinin and gastric inhibitory polypeptide not glucagonotropic in dogs
Sirinek, K. R., Levine, B. A., Crockett, S. E., & Cataland, S. (1980) · Journal of Surgical Research · doi:10.1016/0022-4804(80)90097-9 · Cited by 3
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.671 · Cited by 5
How do different GLP-1 mimetics differ in their actions?
Choukem, S. P., & Gautier, J. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0007-x · Cited by 4
Possible Role of Insulin-Stimulating Hormones in Disturbances of Nutrient Tolerance
Unger, R. H. (1970) · Elsevier eBooks · doi:10.1016/b978-0-12-027361-4.50020-x · Cited by 4
A Critical Account of Synthetic Approaches toward Vildagliptin, an Antidiabetic Drug
Rathod, V. D., Saini, P., Kaur, R., Marimganti, S., & Ranbhan, K. J. (2023) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00048 · Cited by 3
Of mice and men: incretin actions in the central nervous system
Farr, O. M., Pilitsi, E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.013 · Cited by 3
MEYTS, P. D., & Lefèbvre, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00017-1 · Cited by 4
Cantini, G., Trabucco, M., Dicembrini, I., Mannucci, E., & Luconi, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00016-x · Cited by 3
Special Issue: “Anti-inflammatory Effects of Glucagon-like Peptide-1”
Puddu, A., & Maggi, D. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041997 · Cited by 7
White, A., & Levine, R. (1982) · Springer eBooks · doi:10.1007/978-1-4684-1125-6_1 · Cited by 3
Dupre, J., Baer, A. R., Lee, M., McDonald, T. J., Radziuk, J., Rodger, N. W., & Sullivan, S. (1985) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-1850-8_12 · Cited by 3
Identification of enteric hormones with insulin-releasing activity
Johnson, D. G. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90355-6 · Cited by 4
Management of type 2 diabetes: the GLP‐1 pathway
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Future Prescriber · doi:10.1002/fps.39 · Cited by 3
Hormones and metabolism: a background
Blair, E. L. (1983) · Proceedings of The Nutrition Society · doi:10.1079/pns19830017 · Cited by 3
Histoire des incrétines : Du chien brun au monstre de Gila
Schlienger, J.-L. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30071-2 · Cited by 5
Gliptin Therapies for Inhibiting Dipeptidyl Peptidase-4 in Type 2 Diabetes
Green, B. D., Bailey, C. J., & Flatt, P. R. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2010.06.02.19 · Cited by 4
“Fehmann HC, Goke R, Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription, Peptides, 1995;16:1149–52.”
BackgroundDipeptidyl Peptidase IV Inhibitors for Treatment of Diabetes
McIntosh, C. H. S., Kim, S. ‐., Pederson, R. A., Heiser, U. F., & Demuth, H. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch12 · Cited by 3
Physiologie des exokrinen Pankreas
Forell, M. M., STAHLHEBER, H., Lehnert, P., Londong, W., TEUFEL, H., Fritz, H., & Roder, O. (1976) · Springer eBooks · doi:10.1007/978-3-642-66136-5_2 · Cited by 3
Recent Research Developments in Diabetes Mellitus—Part IV
SHARKEY, T. P. (1968) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(21)12072-3 · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
Holst, J. J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.010 · Cited by 3
Molecular Pathology and Therapeutic Strategies of Type 2 Diabetes
Liao, H. Z., Liang, Y., Wang, Y., & Liang, C. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230320162753 · Cited by 4
New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity
Dira, L.-M., Marin, L.-M., Popa, S. G., Singer, C.-E., Coşoveanu, C. S., Donoiu, I., & Golli, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136143 · Cited by 4
“Theories that factors generated by the intestinal mucosa in response to food consumption can stimulate the secretion of “chemicals” from the endocrine pancreas, thereby lowering blood glucose levels, were initiated in the early 1900s [24,25].”
InfluentialDeacon, C. F. (2012) · Diabetes · doi:10.2337/db12-0649 · Cited by 2
“It has been known for over a century that the small intestinal mucosa contains a substance(s) which decreases glucosuria in diabetic patients (1), with the term “incretin” (i.”
Background
Metadata
- Authors
- Moore, B., Edie, E. S., & Abram, J. H.
- Affiliations
- University of Liverpool (GB)
- Carnegie Research Scholar
- Royal Infirmary, Liverpool
- ORCID
- Moore, Benjamin
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1906-01-01
- Volume
- 1
- Issue
- 1
- Pages
- 28-38
- ISSN
- 0306-3283 (ISSN-L)
- PMC
- PMC1276119
- OpenAlex
- W2107757312
- Cited by
- 279
- References
- 0
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 4 · 2020: 4 · 2019: 14 · 2018: 8 · 2017: 4 · 2016: 10 · 2015: 8 · 2014: 3 · 2013: 12 · 2012: 7
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemical Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes mellitus, duodenal mucosa, secretin, pancreatic secretion, pancreatic islets, carbohydrate metabolism, glycosuria, pancreatic hormones, acid extract
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.